543 related articles for article (PubMed ID: 21429940)
1. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Saravolatz LD; Pawlak J; Johnson LB
Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
8. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus.
Borbone S; Campanile F; Bongiorno D; Stefani S
J Antimicrob Chemother; 2010 Mar; 65(3):591-4. PubMed ID: 20083552
[No Abstract] [Full Text] [Related]
9. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Stein GE; Johnson LB
Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
Sader HS; Jones RN; Rossi KL; Rybak MJ
J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.
Huang V; Cheung CM; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2010 Jan; 35(1):25-9. PubMed ID: 19900792
[TBL] [Abstract][Full Text] [Related]
12. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
[TBL] [Abstract][Full Text] [Related]
14. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
16. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC.
Chen H; Liu Y; Sun W; Chen M; Wang H
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):301-3. PubMed ID: 21856109
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
19. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance.
Stefani S; Goglio A
Int J Infect Dis; 2010 Oct; 14 Suppl 4():S19-22. PubMed ID: 20843722
[TBL] [Abstract][Full Text] [Related]
20. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
